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ABSTRACT
Human Respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) are the two major
etiological viral agents of lower respiratory tract diseases, affecting mainly infants, young children
and the elderly. Although the infection of both viruses trigger an antiviral immune response that
mediate viral clearance and disease resolution in immunocompetent individuals, the promotion of
long-term immunity appears to be deficient and reinfection are common throughout life. A possible
explanation for this phenomenon is that hRSV and hMPV, can induce aberrant T cell responses,
which leads to exacerbated lung inflammation and poor T and B cell memory immunity. The
modulation of immune response exerted by both viruses include different strategies such as,
impairment of immunological synapse mediated by viral proteins or soluble factors, and the
induction of pro-inflammatory cytokines by epithelial cells, among others. All these viral strategies
contribute to the alteration of the adaptive immunity in order to increase the susceptibility to
reinfections.
In this review, we discuss current research related to the mechanisms underlying the impairment
of T and B cell immune responses induced by hRSV and hMPV infection. In addition, we described
the role each virulence factor involved in immune modulation caused by these viruses.
KEYWORDS
adaptive immunity; hMPV;
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Introduction
The human Respiratory syncytial virus (hRSV) and
human metapneumovirus (hMPV), which belong to the
Pneumoviridae family,1 are the main viral etiological
agents of severe lower respiratory tract infection (LRTI),
especially in infants, children and the elderly.2,3 HRSV
and hMPV can lead to bronchiolitis and pneumonia,
and have also been implicated in the development of
recurrent wheezing and asthma.2-6
HRSV is the second most common etiological patho-
gen for pneumonia after influenza virus around the
world.7 Furthermore, it has been reported worldwide
between 66,000 to 239,000 deaths per year of children
less than five years of age, who suffered LRTI caused by
hRSV.5,8
HRSV was first isolated in 1956 from a colony of
chimpanzees that presented various symptoms, including
coughing, sneezing, and purulent nasal discharge.9,10 The
illness quickly spread from sick chimpanzees to other
monkeys, indicating the presence of a highly contagious
pathogen that was originally denominated the chimpanzee
coryza agent.10 In 1957, Chanock and Finberg isolated a
similar agent from throat swab samples of infants with a
severe respiratory disease,11,12 which was found to be
identical to the one reported by Blount et al in chimpan-
zees.10 The isolated pathogen induced syncytia formation,
via the virus fusion protein (F) on permissive cell types in
cultures.12,13 Therefore, this pathogen was renamed as a
hRSV.
On the other hand, hMPV was first isolated in 2001
from young Dutch children with a respiratory tract dis-
ease.14 HMPV is a member of the Pneumoviridae family
and Metapneumovirus genus.1 Genomic and phylogenic
analyses suggest that hMPV diverged from avian MPV, a
virus that causes serious respiratory diseases in
chickens.15-17 Infection caused by hMPV presents a
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similar symptomatology as other respiratory viruses such
as hRSV, parainfluenza virus and influenza,18 whereby
the diagnosis is difficult. Symptoms of hMPV include
rhinorrhea, cough, acute otitis media, fever, and, less
frequently, conjunctivitis, rash, diarrhea and vomiting.19
Frequently, risk population, including young children
and the elderly, infected with hMPV require
hospitalization.20 Moreover, mortality as a result of
hMPV can reach up to 10% in the elderly.3,20
Recurrent infections with hRSV or hMPV are common
in children21,22 and adults.21-24 Studies in healthy young
adults subjected to experimental challenge or natural
infection, showed mild upper respiratory symptoms for
both viruses infection.23,25 However, reports performed in
humans and mouse dendritic cells (DCs) have described
that both viruses infect these cells affecting DCs capacity
of promote an adequate immunological memory due to
their interference with na€ıve T cell priming.26-29
The ineffectiveness of the natural infection to induce
long-term immunity has hampered vaccine generation
and currently there is no licensed vaccine available to
prevent the bronchiolitis and pneumonia caused either
by hRSV or hMPV.30-34 However, several candidate vac-
cines are in different stages of development for prevent-
ing the diseases caused by these viral agents. Candidate
vaccines for hRSV and hMPV employ different
approaches, including a chimeric virus (hMPV),35 live
attenuated virus (hRSV),36 and purified proteins
(hRSV),37 among others. Furthermore, recombinant
Bacillus Calmette-Guerin (rBCG) vaccines have been
developed using hRSV and hMPV antigens to provide a
protective TH1 response in mice.
31,38,39 In addition,
antibody-mediated immunity is relevant for protection
against both viruses.40,41 For example, Palivizumab, an
IgG1 humanized anti-F monoclonal antibody, is safe and
effective when given in a prophylactic manner to
children at risk of severe hRSV infection.42 Thus, the
ideal vaccine for either hRSV or hMPV should provide
both antibody and T cell-mediated immune protection.
In this review, we describe the most recent findings
relative to the mechanisms employed by hRSV and
hMPV to evade the host immune system. Further, we
will discuss the virulence factors of each virus that
contribute at modulating the adaptive immune response.
Adaptive immunity triggered by hRSV
The Humoral response against hRSV infection
The humoral immune response plays a major role in
protecting humans from hRSV infections.43-45 Indeed,
high titers of pre-existent mucosal IgG are correlated
with reduced viral loads in hRSV-infected infants.46
Similar correlation have been obtained for nasal IgA
levels in naturally infection and in experimental chal-
lenges in healthy adults.47,48 On the other hand, it has
been described in mice that antibodies play a major role
during reinfection, even more than in the first infection,
giving a principal role to T cells in the clearance of the
virus during the first hRSV challenge.49
Interestingly, prophylactic treatment with Palivizumab
reduces severe hRSV-mediated LRTI,42,50 and conse-
quently diminish hRSV-associated hospitalization of pre-
mature infants, children with congenital heart disease
(CHD) and children with cystic fibrosis (CF),50 suggesting
that a neutralizing antibody of high affinity and titer is
enough to confer a clinical protection against hRSV dis-
ease. However, in most adults antibody titers are under-
neath the levels needed to reach a complete airway
protection, despite repeated infection occurring through-
out life.51 Experimental challenges in healthy adults have
shown that serum and nasal IgA titers increase after infec-
tion but those levels are poorly maintained.47 Similar
results have been reported for neutralizing antibodies lev-
els in a birth cohort followed-up over three hRSV epidem-
ics.52 These antecedents suggest that acute production of
short-life antibody-secreting cells (ACS) is not impaired.
However, a defect occurs in long-lived plasma cells that
arise from the ASC population, which normally should
migrate to bone marrow and respiratory mucosa.47 This
phenomenon might explain, at least in part, as to why the
specific hRSV-IgA generated humoral response is not suf-
ficient to provide protection upon reinfection.
On other hand, several pieces of evidences suggest
that the production of virus-specific antibodies plays an
important role in the regulation of hRSV-specific T cell
responses.53 The interaction between antibodies and T
cell responses was associated with the ratio of neutraliz-
ing and non-neutralizing antibodies. Wherein, for hRSV
infection, a higher ratio of neutralizing versus non-neu-
tralizing antibodies enhanced the balance of CD4C/
CD8C T cells in vitro that respond specifically to the
virus in humans PBMC, as well as in vivo assays in mice
model.54 Interestingly, the infection of mice with hRSV
immune-complexes increase the immune response
against the virus, particularly promoting a TH1 response
by CD4C T cells and IgG2c response by B cells.55 Higher
amounts of non-neutralizing antibodies might enhance
infection and could cause immune complex deposition,
leading to enhanced respiratory disease.56 Considering
the whole body of data described above, it is possible to
hypothesize that hRSV infection can modulate the
humoral response to impair recurrent reinfection and
indirectly affect T cell activation.
686 A. E. GONZALEZ ET AL.
The cellular immune response against hRSV
infection
Both memory CD4C and CD8C T cells contribute signifi-
cantly at achieving protective immunity upon hRSV
infection.57-59 This applies especially in children with
defective T cell responses, who exhibit severe hRSV
infection and prolonged virus shedding.60 Supporting
this observation, T cell depletion assays in BALB/c mice
results in higher hRSV replication upon infection, while
the adoptive transfer of virus-specific memory T cells
enhances virus clearance in recipient mice.61 Further-
more, it has been demonstrated that transfer of hRSV-
N-specific T cells also contribute to reduce viral immu-
nopathology.38,39 Moreover, memory T cells appear to be
clinically important in protecting from severe diseases
caused by hRSV reinfections. This notion is supported
by the fact that minor symptoms are observed in popula-
tions of older children and young adults infected with
hRSV, despite of defective responses in IgA B cell mem-
ory and in hRSV-specific serum.47,62
Recently, it has been demonstrated that tissue-resi-
dent memory (Trm) T cells are relevant to the capacity
of the host to rapidly limiting the spread of pathogens in
tissues.63,64 Thus, hRSV-specific CD4C and CD8C Trm T
cells could provide immediate immunological protection
against hRSV infections. In fact, analyses of hRSV-spe-
cific CD8C memory T cells have shown that these cells
mostly remain in lungs and a minority of these cells cir-
culates in peripheral blood from healthy individuals.65,66
Moreover, increased activated hRSV-specific airway Trm
T cell frequencies were observed in bronchoalveolar
lavage fluid (BALF) from healthy adults inoculated with
hRSV, which coincided with a reduction in the viral
load.59
hRSV-mediated lung pathology in mice is not
completely dissected and primary reports attributed this
effect to T cells, specially CD8C T67,68 but in humans, it
has mostly been associated with a large influx of neutro-
phils in the lungs of patients with bronchiolitis, as well as
in fatal cases of infants.69-71 It is suggested that neutro-
phils recruitment induced by hRSV infection promote
lung damage through the generation of reactive oxygen
species and extracellular traps (NETs).72,73
Nevertheless, a recent study using experimental hRSV
infection of adults in which a 65% of individuals pre-
sented inflammation symptoms, has shown that the virus
replicate in the lower respiratory tract, inducing cellular
infiltration of CD8C T cells to the airways.59 Consistent
with this notion, there is evidence that CD8C T cells can
cause immunopathology in infants when a high amount
of CD8C T cell encounter a large number of hRSV par-
ticles in the tissue.74 However, the drawback of these
studies is that no other cell types were evaluated, therefore
it is not possible to rule out the neutrophils contribution
to the pathology. In addition, another study showed that
T cell responses are reduced or absent in exacerbated
lungs of fatal cases of infants infected with hRSV, who
had a severe LRTI caused by this virus.71 In these tissues
a positive staining for macrophages and neutrophils was
observed.71 Thus, in more severe cases of infantile viral
LRTI caused by hRSV infection, lung inflammation
appears to be due to a pronounced infiltration of neutro-
phils and macrophages.
CD4C T cell response against hRSV and mechanisms
of evasion used by the virus
An adequate CD4C T cell response can efficiently aid at
reducing viral load upon hRSV infection.39 Indeed, it has
been reported that adoptive transfer of CD4C T cells
from immunized mice with a prototype vaccine consist-
ing in a recombinant rBCG expressing hRSV N protein
(rBCG-N-hRSV), resulted in a significant reduced viral
load in the lungs after infection in recipient mice, thus
providing a protective TH1 antiviral response.
38 These
data suggest that CD4C T cells itself stimulated with the
proper antigens in can significantly contribute to hRSV
clearance.
However, in infants and children naturally infections,
an inefficient adaptive immune response occurs, which is
characterized by 1) a skewed TH2 immune response;.
75,76
2) a deficient anti-viral TH1 response and 3) a low secre-
tion of IFN-g and TNF-a in peripheral blood mononu-
clear cells77 and in nasopharyngeal aspirates,78
respectively. Nevertheless, hRSV-infected infants suffer-
ing from bronchiolitis present higher levels of TNF-a in
BALF at day 1 of intubation, as compared with controls.
This observation suggest that a mixed TH1/TH2 response
is generated at the first stage of the disease.79 Consis-
tently with this observation, a mixed TH1/TH2 response
was also observed in the lung of hRSV-infected mice,
although with a significant increase of IL-13, which is
known to induce airway hyperreactivity.80,81
The predominant TH2 immune response observed in
infants and children could be due to the capacity of
hRSV to polarize the adaptive immune response from a
protective TH1 phenotype to a TH2-type response.
76
However, whether a pathogenic TH2 immune response
significantly contributes to disease in at-risk human
groups remains to be demonstrated.
Importantly, in vitro studies have described that
hRSV-infected mouse DCs are unable to properly acti-
vate T cells,27 due to an impairment of immunological
synapse formation. This study evaluated the formation
and functionality of the immunological synapse between
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OT-II CD4C T cells with hRSV-infected DCs, pulsed
with OVA peptide,27 showing a lack of sustained immu-
nological synapse as well as reduced secretion of cyto-
kines from OT-II cells, as compared with uninfected
controls. This phenomenon was observed by using na€ıve
T cells, in contrast, it has been described that memory/
effector T cells have different responses, which is less
affected by hRSV-infected DCs.82 This phenomenon,
could explain why healthy adults infected with hRSV can
clear the virus and not in young children who have no
memory T cells.
TH2 polarization also is induced by Tymic-stromal
lymphoprotein (TSLP), an epithelial cell-derived cyto-
kine that signals through the TSLP receptor (TSLPR).83
This cytokine potently activates myeloid DCs (mDCs),
since these cells are known to express high levels of the
TSLPR.84 Then, TSLP-stimulated DCs upregulate OX40
ligand (L) cell surface expression and produce TH2 cell-
attracting chemokines, including CCL17 and CCL22.84
Indeed, TSLP from in vitro hRSV-stimulated rat AECs
induced the functional maturation of mDCs and
enhanced the surface expression of the thymus-activa-
tion-regulated chemokine (TARC) and OX40L on
DCs,85 which induce mainly inflammatory TH2-polar-
ized immune responses.86 Experiments performed in
BALB/c mice infected by hRSV shown elevated levels of
TSLP protein in lungs compare with uninfected con-
trol.80 The role of TSLP in the promotion of Th2
response under hRSV infection was evaluated using a
TSLPR-deficient (TSLPR¡/¡) mice. These studies shown
a decrease hRSV-mediated immunopathology in this
model after infection. In addition, analysis of superna-
tant fluids of re-stimulated mediastinal lymph nodes
(MLN) of TSLPR¡/¡ mice infected with hRSV show a
significant decrease of IL-13 and IL-5 production, as
compare with WT mice, but both mice produced equiva-
lent levels of IFN-g and IL-17A. These results support,
the notion that TSLP is required to TH2 polarization.80
In other studies, it has been shown that the TSLP-
OX40L –OX40 axis contributes to the hRSV-induced air-
way hyperresponsiveness (AHR) and inflammation after
reinfection of mice that were initially infected as neo-
nates. Further, administration of an anti-OX 40L anti-
body treatment during primary infection as neonates
prevented the enhancement of the AHR upon reinfection
5 weeks later.86 Moreover, treatment with the anti-
OX40L during primary infection in newborn BALB/c
mice reduced the TH2 cytokines IL-5 and IL-13 in BALF
upon reinfection.86
The pathogenic role of CD4C T during re-infection
with hRSV in adult mice, after being infected as neo-
nates, can be explained by the induction of an exagger-
ated TH2 response, demonstrated by the cytokine profile
observed in these animals.87 This could be explained, at
least in part, by the upregulation of the IL-4Ra. Specific
deletion of the IL-4Ra. gene in CD4C T cells abolished
hRSV-induced airway AHR and lung damage upon rein-
fection with hRSV.87 However, these results are contro-
versial because several reports have shown that CD4C T
cells are required for the clearance of the virus and to
promote antibody response against hRSV.60,88-90 In this
sense, it seems that dysregulation of CD4C T cells pro-
mote harmful Th profiles but these cells are still required
for hRSV clearance.
Additionally, an IL-17-mediated TH17 response is a
possible third type of immune response associated with
the respiratory pathogenesis induced by CD4C T cells
during hRSV infection.91,92 Indeed, binding of IL-17 to
its receptor promotes an inflammatory response and
increased viral loads in the lungs of infected BALB/c
mice.92 Stimulation of T cells with hRSV-infected human
bronchial epithelial cells (HBEC) induced the production
of IFN-g, IL-4, and IL-17, suggesting that hRSV can acti-
vate these three TH cell subsets.
93 Consistent with the lat-
ter, stimulation of PBMC from healthy donors with
hRSV infected A549 cells induced the production of
IFN-g and IL-4.94 In other studies, the concentration of
IL-17 in nasopharyngeal aspirates of children during
hRSV infection was higher at the moment of discharge
of the hospital.95 However, the data are controversial
since the latter was only valid for infants that do not
require ventilation.95
In addition to these mechanisms used by hRSV to
avoid the CD4C T other studies have demonstrated that
IL-25 and IL-17RB are expressed in lungs of hRSV-
infected BALB/c mice and their expressions correlate
with potentially pathogenic cytokines, such as IL-13
(TH2), IL-5 (TH2) and IFN-g (TH1), promoting the
hRSV-mediated lung disease.91
Finally, using a mouse model, it has been demon-
strated that antibody-mediated depletion of neutrophils
decreased the number of IL-13 producing CD4C T cells,
as well as TNF-a and mucin production, when compare
with the isotype-control treated group upon hRSV infec-
tion, suggesting that an interaction of neutrophils and
CD4C T cells occurs during hRSV infection.96 On the
other hand, has been described that neutrophils can have
a APC-like phenotype expressing costimulatory mole-
cules and activating CD4C T cells polarizing to a TH1/
TH17 phenotype in inflammatory mouse model, but for
hRSV infections this phenomenon has not been demon-
strated yet.97,98 This could be an important unexplored
area because has been described that hRSV can infect
human neutrophils. Indeed, it has been possible to mea-
sure F, G and N proteins and viral RNA on those cells,99
suggesting that neutrophils can uptake virus in the
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airways of infected children and then present antigens to
T cells, but further evidence is necessary to support this
idea.
Taken together, data derived from in vivo and in vitro
studies suggest that hRSV infection in the lung can
induce different mechanisms to prevent an efficient
CD4C T cell proliferation and differentiation into protec-
tive antiviral memory or effector cells of the host.
CD8C T cell response against hRSV and mechanisms
of evasion used by the virus
It is well documented that CD8C T cells are pivotal at
controlling respiratory viral infections, such as the one
caused by hRSV.57 Indeed, data from an adoptive trans-
fer model demonstrated that transfused hRSV H2-Kd-
restricted Cytotoxic T lymphocytes (CTLs) specific for
the M282–90 (KdM282) epitope, the most predominant
one of the M2 protein recognized in vivo (dominant epi-
tope)100 rapidly clear the virus from the lungs of recipi-
ent BALB/c mice. However, a significant lung pathology
was also observed.67 Consistent with that observation,
BALB/c mice immunized with a DNA vaccine expressing
the KdM282 epitope linked to human b2-microglobulin
(b2m) developed an enhanced pulmonary inflammatory
response after hRSV challenge, characterized by
enhanced weight loss.101 Likewise, intranasal administra-
tion of the KdM282 epitope combined with Escherichia
coli heat-labile toxin (LT)/LTK63 elicited a strong antivi-
ral CD8C T-cell response in BALB/c mice, but also
enhanced lung pathology.102 This data indicates that the
KdM282 epitope-specific CD8
C response is associated
with enhanced disease. In addition, Ruckwardt et al.103
demonstrated that infection of CB6F1/J mice with a
recombinant hRSV containing a mutation in the domi-
nant KdM282 epitope resulted in an increased response
of CD8C T cells specific for the subdominant epitope
DbM187 (M187-195) with significantly less clinical disease.
In contrast, hRSV containing mutations in this subdomi-
nant epitope induced an augmented KdM282-specific
CD8C T cell response and increased severity of illness.103
Consistent with the latter, in CB6F1 hybrid mice, which
recognize multiple MHC class I-restricted epitopes, it
was described that DbM187 specific CD8
C T cells control
hRSV replication more efficiently with less pulmonary
inflammation and illness than the KdM282 specific CD8
C
T cells.104 In addition, another study has shown that after
immunization with a recombinant PR8 influenza virus
carrying the subdominant hRSV KdF85 epitope, KdF85-
specific CTLs were induced in BALB/c mice with a sig-
nificant reduction of the viral load in the lungs upon
hRSV challenge,105 indicating a protective effect against
this virus. Taken together, these results from the mouse
models suggest that a subdominant epitope-specific
CD8C T cell response could be more beneficial to the
host by promoting an effective anti-viral immune
response and reduced lung disease, than the dominant
ones, which promote a robust anti-viral immune
response but also an enhanced lung pathology upon
hRSV infection.
Likewise, when CD8C T cells from rBCG-hRSV-N
immunized-BALB/c mice are stimulated with hRSV N
peptides, these cells produce significant amounts of IFN-
g, partially protecting recipient mice of hRSV infection.38
The efficiency of the CD8C T cell-mediated virus control
could depend on how the hRSV antigen is presented by
DCs, since less IFN-g secretion was observed when
BALB/c mice were immunized with purified hRSV N or
M2 in alum, compare with when mice immunized with
rBCG-N-hRSV and rBCG-M2-hRSV.38 Furthermore,
CD8C T cell-mediated virus control and immunopathol-
ogy is dependent on IFN-g production during early
infection.67
In human, has been described lesser about single epi-
tope immune-modulation, in fact the majority only
describe hRSV-derived peptides that induce IFN-g secre-
tion by stimulated T cells,59,106,107 but they do not
address their possible role during pathology. Table 1,
summarizes the hRSV epitopes described so far for
HLAs. It is possible that these epitopes are implicated in
CD8C T cells response but further studies are required to
demonstrate if these specific T cells response is favorable
or harmful for an infected person.
The impairment of CTL function appears to be
another immune evasion mechanism evolved by hRSV.57
How specific hRSV proteins affect these cells will be dis-
cussed below, but here additional mechanisms that have
not been related yet to specific hRSV proteins. For
instance, the upregulation of the programmed-death
ligand 1 (PD-L1), which binds PD-1 on CD8C T cells in
human bronchial epithelial cells (BECs), occurs after
hRSV infection and it has been shown to cause a
Table 1. hRSV epitopes described for HLA.
Protein Epitopes HLA Reference
N N peptides HLA-A02 and HLA-B08 106
(NPKASLLSL [NPK] HLA-B07:02 59
QVMLRWGVL [QVM]) HLA-B07:02 59
M2 M2(151-159) HLA-A
03 107
M2(64-72)) HLA- B44
107
NS1 (LSDSTMTNY [LSD]) HLA-A01:01 59
NS2 NS241-49 HLA-B51
107
(FLVNYEMKL [FLV]) HLA-A02:01 59
L (IPAYRTTNY [IPA]) HLA-B07:02 59
M M195-203 HLA-B51
107
M229-237 HLA-A1
107
YLEKESIYY [YLE] HLA-A01:01 59
VTDNKGAFKY [VTD]) HLA-A01:01 59
G (KPNIRTTLL [KPN] HLA-B07:02 59
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functional impairment of CD8C T cells.150 Indeed, block-
ing PD-L1 with a specific-antibody in hRSV-infected
BECs, co-cultured with CD8C T cells, enhances CD8C T
cell effector functions and decreases hRSV gene expres-
sion in BECs.108
In addition, CD8C T cells may not only be directly
influenced by the impairment of the T cell priming by
DCs, but also be indirectly affected by the modulation of
cytokine environment, as NK cell-derived IFN-g produc-
tion precedes lung CD8C T cell recruitment,109 in a
mechanism similar to the Influenza A virus.110 Also, tem-
porally association has been made between CD8C T cells
and neutrophils, where an important influx of neutro-
phils to the airways in infants occurs before CD8C T cells
activation. This initial neutrophil influx correlates to the
expression of the most severe hRSV symptoms suggesting
that the inflammatory environmental potentiated by neu-
trophil influx could modulate CD8C T cell response.111
In summary, CD8C T cell function appears to be
impaired by hRSV through different mechanisms.
Nonetheless, these different strategies used by this virus
in targeting the CD8C T cell response may not be that
relevant in populations of older children and young
adults, since most of them have mild symptoms or are
asymptomatic when undergoing hRSV viral infection.
Role of hRSV Proteins in Immunomodulation
The hRSV genome consists of a 15.2 kb long, negative
sense RNA, which contains 10 genes encoding for 11
proteins, with two overlapping open reading frames
encoding two proteins: M2-1 and M2-2 (Fig. 1).112,113
Several hRSV proteins play a role in evading the immune
system of the host (see Table 2). The hRSV glycoproteins,
located in the viral envelope, that have been involved in
interfering the immune response of the host are:
HRSV Glycoprotein protein (G): this protein is
involved in virus attachment114 and it also exists as a
secreted form, which prevents opsonization and neutrali-
zation of hRSV by anti-G specific antibodies.115
Figure 1. Viral Structure and Genome Organization of hRSV and hMPV. Schematic representations of hRSV and hMPV structures are
shown. Both are negative single-stranded RNA (30 to 50), enveloped viruses that mainly differ in the number and order of genes in their
genomes. These genes encode for P, N, SH, G, F, L, M, and M2 proteins, which are similar for both viruses. The M2 gene has an open
reading frame that encodes for the M2-1 and M2-2 proteins. The hRSV genome also contains the non-structural proteins NS1 and NS2,
which are absent in hMPV.
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Moreover, the secreted form of the G protein has a che-
mokine-like motif (CX3C) that competes with fractal-
kine (CX3CL1) in binding to its receptor CX3CR1, thus
reducing the CX3CR1C T cells response.116
HRSV Fusion (F) protein: this viral protein is required
for the fusion of viral particle with the host cells4 and also
play a direct role in the ability of hRSV to decrease the pro-
liferation of these cells by contact.117 In fact, when Vero
cells express the F protein or are infected with a version of
hRSV that only have F protein on its surface, they reduce
the proliferation and response to mitogen stimulus.117
HRSV small hydrophobic (SH) protein: it is thought
that this protein works as an important viroporin during
hRSV pathogenesis.118 This protein also inhibits apopto-
sis in order to promote viral replication, as recombinant
hRSV lacking the SH protein induced a significant cyto-
pathic effect in different cell lines, compare with WT
hRSV.119 In addition, the hRSV SH has been shown to
inhibit the NF-kb pathway through a decrease in the
TNF-a production in mouse fibroblastic cells.119
Another studies have demonstrated that glycoproteins
affect the innate and adaptive immune response to hRSV.
In this study, immunization of BALB/c mice with a recom-
binant strain of hRSV lacking both G and SH (CP52)
increased the number of pulmonary natural killer (NK)
cells, as well as the levels of IFN-g and TNF-a at day 3 p.i.
with a concordant reduced expression of the TH2 related
cytokines (IL-4 and IL-6) when compare with the parental
RSV strain (B1).120 However, in the same study it was also
shown that during primary infection, RSV-specific MHC II
CTL precursor frequencies were delayed in CP52-immu-
nized mice compare with B1-immunized mice in BALF,
cervical lymph nodes and spleen at day 5 p.i.120 Further-
more, during secondary infection, both RSV-specific MHC
I and MHC II CTL precursor frequencies were delayed in
spleen at day 3 p.i in CP52- immunized mice, as compare
with mice immunized with B1 or control Vero cell lysate.120
Altogether these data suggest that the hRSV G and/or SH
proteins play a role in: a) downregulation of specific NK
cell response, as mutants lacking these proteins increase
pulmonary NK cells; b) polarization toward a TH2 immune
response, as RSV strains deficient in these proteins decrease
TH2 related cytokines.
Beside glycoproteins, hRSV also expresses other pro-
teins involved in the impairment of the host’s immune
response, which are described below.
HRSV Non-structural (NS) proteins 1 and 2: these
proteins impair the type I IFN pathway by targeting the
Table 2. Function of hRSV and hMPV proteins and their roles modulation of immune response.
Protein Function Role in Immunomodulation
Protein/Gene
hRSV hMPV hRSV hMPV References
G Attachment to host cells Attachment to host cells -Evasion of the anti-G antibody
functions.
Inhibition of the type I IFN
pathway (RIG-I)
114-116,155,156
-Impairment of CX3CR1C T cell
migration and function
(CX3C motif).
F Fusion of viral particle
with host cells
Interfere with the proliferation
of T cells by contact.
N/A 4,117
SH Virioporin Virioporin - Inhibition of apoptosis. -Inhibition of the NF-kB
pathway
118,119,157
- Inhibition of TNF-a-mediated
NF-kB signaling and NF-
kB activation.
NS1 N/A Impairment of the type I IFN
pathway. (IRF-3)
N/A 121-127
NS2 N/A Impairment of the type I IFN
pathway
N/A 121-127
M2.1 Transcription anti-
terminator factor
Involved in viral
replication through its
Zinc binding domain
Activation of the NF-kB pathway N/A 52,53,145,160,161
M2.2 Regulatory factor in
replication and in
transcription
Regulatory factor in
replication and in
transcription
N/A Inhibition of the type I IFN
pathway (Interaction
with MAVS).
112,128,162,163
N Assembly of the
nucleocapsid and
protection of the viral
RNA
Interaction with the viral
RNA
-Interference with the immune
synapse assembly.
N/A 129-131
- Inhibition of the Type I IFN
pathway by MAVS
interaction
M Viral particle assembly Viral particle assembly N/A It induces: 158,159
- Maturation of
monocyte-derived
DCs.
- Secretion of pro-
inflammatory
cytokines.
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interferon-regulatory factor 3 (IRF3), thus inhibiting the
IFN-a/b antiviral signaling.121 Additionally, these NS
proteins suppress human DC maturation by downregu-
lation of the type I IFN production; inhibit apoptosis;
control protein stability; and regulate host cell
mRNA.122-125 Moreover, the NS2 protein induces cell
rounding and shedding in vivo in hRSV-infected human
ciliated cells in the large airways,124 promoting the
reduction of viral titers in the airway mucosa and initiat-
ing the obstruction of distal airways.124 In studies using
co-cultures of WT or mutant hRSV-infected human DCs
with autologous CD4C T cells, it has been demonstrated
that NS1 protein promotes CD4C T cell proliferation
with a TH2 immune response.
126 In addition, NS1 was
shown to suppress the CD8C T cell anti-viral response,
as there were increased levels of IFN-g in the superna-
tant of lymphocytes co-cultured with human DCs
infected with hRSV DNS1 as compare with lymphocytes
co-cultured with DCs infected with WT RSV.126 In the
same study, it was also shown that NS1 suppresses the
CD8C CD103C T cell activation and proliferation, which
is required to accomplish the cytolytic function of these
cells at the mucosal epithelium of the respiratory tract.126
Therefore, the hRSV NS1 protein can impair the efficient
anti-viral function of CD8C T cell in different manners.
Further, in vivo suppression of the CTL response by
hRSV is mediated by NS2, as BALB/c mice infected with
a hRSV mutant deficient in the NS2 gene (DNS2) or
both the NS1 and NS2 genes (DNS1/DNS2) showed
increased pulmonary hRSV-specific CTL responses com-
pare with those of mice infected with WT hRSV or with
the virus lacking NS1 (DNS1).127
HRSV M2–1 protein: This is a transcription anti-ter-
mination factor important for the efficient synthesis of
full-length viral mRNAs.112 However, M2–1 has also
been shown to activate the NFkb pathway as demon-
strated by translocation to the nuclei of the NFkb factor
in A549 cell transfected with a M2–1 encoding vector.128
HRSV N protein: This protein is critical for the
assembly of the hRSV nucleocapsid and protection of
the viral RNA (Fig. 1).129 Furthermore, the hRSV N pro-
tein interfere with the type I IFN pathway by targeting
the mitochondrial antiviral signaling protein (MAVS),
thus inhibiting the MAVS-dependent antiviral path-
way.130 Moreover, hRSV-infected DCs are unable to acti-
vate na€ıve CD4C T cells in vitro probably due to the
impairment of the immunological synapse assembly by
the hRSV N protein expressed at the host cell membrane
(Fig. 2, upper left box), rendering T cells unresponsive to
subsequent TCR engagement..27,93,131 Specifically, the
Golgi apparatus polarization within T cells, an event
needed for a proper immunological synapse assembly, is
barely detectable in T cells co-cultured with hRSV-
infected DCs, in contrast to T cells co-cultured with
mock-inoculated DCs.27 Moreover, impairing this signal-
ing event significantly decreases tyrosine phosphoryla-
tion of TCR-associated CD3z-chain tyrosine-based
activation motifs (ITAM) by LCK,132 in na€ıve T cells
stimulated with a cognate antigen.27 Furthermore,
immune synapse assembly inhibition is accompanied by
a reduced binding of ICAM-1, suggesting that the N pro-
tein interferes with receptor-ligand interactions at the
immunological synapse, reducing the TCR clusters that
are usually observed within a mature immunological
synapse.131 A putative viral mechanism of this inhibitory
effect could be the interaction of the hRSV N protein
with an element of the TCR complex, since central clus-
tering of this protein occurs alongside the TCR, even in
the absence of pMHC.131 Further studies are required to
define the molecular mechanisms underlying the
immune synapse inhibition by RSV infection.
Adaptive Immunity Triggered by hMPV
The humoral response against hMPV infection
It has been described that hMPV-specific antibodies are
produced after hMPV infection in the childhood. The
most predominant antibodies detected are anti-F antibod-
ies after the first infection and can be detected over the
time at least for 20 y evidenced by the fact that 95% of
20 y old individuals are seropositive for the F protein.133
Likewise, it has been described that individuals with low
levels of anti-hMPV antibodies are more susceptible to
hMPV infection.134 Studies in BALB/c mice have demon-
strated that passive transfer of hyper-immune hMPV-spe-
cific mouse sera to na€ıve mice decreased virus titer, seven
days post-infection, suggesting that hMPV-specific anti-
bodies provide a level of protection from viral chal-
lenges.135 However, the hMPV-specific antibody response
appears to be inefficient in mediating viral clearance,
since hMPV persists in lungs of infected mice despite the
presence of neutralizing antibodies.136 In fact, it has been
observed that in humans hMPV can persist in immuno-
compromised patients, suggesting a principal role of
immune response for control hMPV infection.137,138 This
could be explained by a waning effect on protective
hMPV-specific antibodies over time, or the levels of these
antibodies may not be sufficient to protect from a re-
exposure to hMPV infection.134 Moreover, in hMPV-
infected BALB/c mice, seroconversion and the develop-
ment of neutralizing anti-hMPV specific antibodies (IgG,
IgG1, and IgG2a) are observed post-challenge, but these
antibodies do not prevent the persistence of infectious
hMPV.136 In humans, from 257 hMPV-positive individu-
als, only a 25% remained asymptomatic, whereas 75%
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presented symptoms, despite their severity.134 hMPV-
infected individuals presented low IgA and IgG titer com-
pare with non-infected individuals, and also lower neu-
tralizing capacity, consistent to what is observed in
mice.134 Therefore, the humoral responses raised against
hMPV following natural infection might not be sufficient
to reduce re-infection episodes.22
The cellular response against hMPV infection
For hMPV, it was recently shown that the presence of
virus-specific T cells in airways and in lungs of BALB/c
mice, are associated with an effective anti-viral immune
response.139 These data suggest that Trm T cells could also
be important for controlling hMPV infection. However,
further studies are still required, especially in humans.
CD4C and CD8C T cells are required for the clearance of
hMPV from infected lungs in hMPV-infected BALB/c
mice.140 Likewise, an efficient anti-viral immune response
based on IFN-g-secreting CD4C and CD8C effector and
memory T cells is necessary for preventing the spreading of
hMPV in airways and to avoiding the development of
bronchiolitis and pneumonitis. This is supported by a
study, that used a candidate vaccine based on rBCG
Figure 2. Effect of hRSV and hMPV Infections on T cell Activation. To induce proper T cell activation by DCs presenting a specific antigen,
the following three signals are required to establish a mature immunological synapse: i) interaction between MHC molecules (class I or
II) and the TCR molecule; ii) co-stimulation of molecules, including CD80, CD86, and CD28; and iii) T cell-polarizing molecules, either sol-
uble or membrane-bound. Additionally, adhesion molecules, such as the intracellular adhesion molecule 1, are also involved. In the
amplified diagrams, the possible mechanisms by which hRSV or hMPV are able to impair antigen presentation are shown. In the case of
hRSV (upper left box), the virus interferes with the immunological synapse through its N protein, which impairs Golgi polarization and
TCR signaling. This inhibitory effect is accompanied by reduced intracellular adhesion molecule 1 binding to the lymphocyte-function
associated antigen 1 (red arrow). In the case of hMPV (upper right box), the virus impairs TCR signaling and, consequently, T cell
activation through an unknown soluble factor, which does not affect the immunological synapse itself.
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expressing hMPV antigens, where vaccination with this
hMPV vaccine expressing the M2–1 or P protein protects
BALB/c mice from hMPV-mediated lung pathology and
reduced viral load in lungs.31 However, this virus also
evades these effective anti-viral immune responses.26 More-
over, na€ıve BALB/c mice were shown to develop a biphasic
immune response in vivo after hMPV infection.135 During
the first week, a TH1 response initially controls virus repli-
cation before polarizing toward a TH2 immune response
that facilitates viral persistence.135,136 A recent in vivo study,
though, showed mixed TH1 and TH2 responses during the
first week of hMPV infection in BALB/c mice.141 Consis-
tent with the notion observed in the mouse model, in adults
undergoing hMPV infection, it has been described that
PBMCs from these patients presented cytolitic activity, as
evaluated by a Chrome-release assay, which suggest a TH1
response.142 However, PBMCs, from healthy adults, stimu-
lated with heat-inactivated hMPV promotes the induction
of high levels IL-6 (a TH2 polarizing cytokine that prevents
TH1 differentiation
143) and low levels of IFN-g and CCR5
(TH1 cytokines) when compare with hRSV-stimulated
PBMCs, thus suggesting a polarization toward a TH2
response.144 In contrast, other studies demonstrate that
infants undergoing hMPV infection presented lower levels
of pro-inflammatory cytokines compare with infants
undergoing hRSV or influenza infection, including TNF-a
and IL-1b, two cytokines related to the chemotaxis of neu-
trophils in lungs, as well as IL-12, IL-6 and IL-8.145 Further-
more, in infants undergoing hMPV infection it was
observed that a predominant TH1 response is generated,
since it was detected an increase in the IFN-g/ IL-4 ratio in
nasal airway secretions. Taken together, this data indicate
that hMPV induces a complex immune response, which
might include a mixed TH1/TH2 response, similar to what
was observed in mice, though further studies are required
to evaluate the T cell response in humans upon hMPV
infection.
CD4C T cell response against hMPV and mechanisms
of evasion used by the virus
HMPV has also evasion mechanisms to interfere specifi-
cally with CD4C T cell function that do not promote an
efficient antiviral immune response and enhances lung
pathology. Specifically, depletion of CD4C T cells in
hMPV-infected BALB/c mice reduces lung pathology
and airway obstruction, without affecting viral loads.140
These data demonstrate that the subset of CD4C T cells
contributes to lung pathology but they are not critical for
viral clearance.
As has been mentioned above, hMPV can induce a
mixed TH1/TH2 response and this type of response is
dependent of activation of TSLP pathway, which favors
TH2 response over TH1 response that is known is neces-
sary for hMPV clearance. Related to this, hMPV infec-
tion has been proven: to promote TSLP expression in
both human AECs and mouse lungs; to stimulate
OX40LCCD11bCDCs lung infiltration; and to increase
the levels of pro-inflammatory TH2 cytokines-producing
T cells, including TARC, IL-5 and IL-13, but also TNF-a
in BALB/c mice,141 as previously reported for OX40L on
TSLP-activated DCs.86 Moreover, TSLPR¡/¡ mice
showed decreased lung inflammation and hMPV replica-
tion, as well as a higher frequency of CD8C and CD4C T
cells.141 These findings highlight the possibility that a
repertoire of virus-specific TH and CTLs may incom-
pletely eliminate infected cells within the airways follow-
ing primary infection, leading to an exacerbated
inflammatory response, mainly mediated by the TSLP
pathway, thus inducing an aberrant T cell response.141
Moreover, hMPV-infected DCs, similarly to hRSV-
infected DCs, also impair the activation of CD4C T cells.
Upon stimulation with hMPV-infected and antigen
loaded DCs, na€ıve antigen-specific CD4C T cells dis-
played significantly reduced proliferation, expression of
surface activation markers, such as CD25 (IL-2 receptor/
IL-2Ra), CD69 and CD71 (transferrin receptor) and IL-
2 secretion, as compare with T cells stimulated with
uninfected control DCs.26 However, this inefficiency is
not due to a deterioration of the immune synapse assem-
bly since both TCR cluster formation and Golgi polariza-
tion still occur (Fig. 2, upper left box).26 This impairment
may contribute to a delayed TH1 response. Indeed, CD4
C
T cells elicit a poor IFN-g response when activated with
hMPV-infected human peripheral blood mononuclear
cells in vitro,144 suggesting that these hMPV-infected
cells can also inhibit the function of CD4C T cells to
stimulate an efficient antiviral TH1 immune response in
humans. The impairment of T cell immunity could be
the result of impaired DC functions by hMPV, possibly
through of a soluble factor derived from hMPV-infected
DCs, as supernatants from these infected cells impairs T
cells activation when stimulated by plate-bound anti-
CD3e and anti-CD28.26 Thus, hMPV impairs the TCR
signaling, without disturbing the immune synapse for-
mation and Golgi polarization in T cells26 (Fig. 2, upper
right box). Consistent with the latter, the SH and/or G
proteins reduced CD4C T cell proliferation in a co-cul-
ture assay of hMPV-infected MDDC with CD4C T cells
when compare with T cells co-cultured with DSH/G
hMPV-infected DCs.146 Likewise, in vitro studies show
that human and mouse hMPV-infected DCs lose the
capacity to activate and expand na€ıve T cells, although to
a lesser degree than hRSV-infected DCs.26,146-148
Furthermore, the neutralizing antibodies detected in
mice after hMPV infection, appear to be dependent on
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CD4C T cells, because no detectable neutralizing anti-
bodies were observed in hMPV-infected mice depleted
of CD4C T cells.140
CD8C T cell response against hMPV and mechanisms
of evasion used by the virus
In a similar manner as for hRSV, CD8C T cell response
specific to hMPV antigens is critical for an effective viral
clearance, as demonstrated in studies using vaccine can-
didates against hMPV, such as virus-like particles har-
boring hMPV F or hMPV M antigens.149 Supporting this
notion, hMPV-specific effector CD8C T cells, in BALB/c
mice that lack protective anti-hMPV antibodies and in
the absence of CD4C T cells, no detection of virus load
and reduction of lung disease were found upon hMPV
infection, suggesting that the cytotoxic activity of CD8C
T cells alone can confer protection against hMPV140 and
highlighting the importance of CD8C T cells in control-
ling hMPV infection. Moreover, when specific hMPV
M2 CTLs were transferred into RAG-1¡/¡ mice, these
lymphocytes protected the host of hMPV challenge.150
Furthermore, hMPV-specific IFN-g-producing CD8C T
cells can be found in the mucosa of the airways and in
lungs, but not in the lymph nodes or in spleen of hMPV-
infected BALB/c mice at 7 d p.i, suggesting the activation
of the Trm T cells specific for hMPV epitopes.139 Never-
theless, hMPV-virus specific CTLs were also induced 21
d p.i in spleen.139 These data underscore the importance
of Trm CD8C T cells in controlling rapidly hMPV infec-
tions. Recently, in human has been described that mem-
ory CD8C T cells are reactive to the majority of hMPV
proteins (M, F, G, M2-1, N and SH) and particularly,
CD8C T cells that recognize M and F protein can secrete
IFN-g after 21 months post-infection.142 Nevertheless,
further studies are required in humans to clarify if this
CD8C T cells populations are protective or not, because
independently of the presence of this population, hMPV
keeps its capacity to generate re-infection episodes.
Recent studies associate the lack of the type I IFN
pathway with CD8C T cell impairment.151 In fact, hMPV
infected-IFNAR¡/¡ mice had a higher peak of early
viral replication, less airway dysfunction and lung
inflammation, but cleared the virus with the same kinet-
ics as observed in WT mice.151 Likewise, CD8C T cells
from IFNRA¡/¡ mice expressed similar levels of PD-L1
when compare with CD8C T cells from WT mice. How-
ever, these cells showed an upregulation of the inhibitory
receptor TIM-3, thus impairing the CD8C T cell func-
tion.151 Additionally, CD8C T cells can be impaired by
hMPV in a PD-1 dependent manner, similar to hRSV, as
lung CD8C T cells are impaired in HLA B7.2 transgenic
(B7tg) mice and had upregulated PD-1.152 Conversely,
blocking of PD-1 by administration of monoclonal spe-
cific antibodies in B7tg mice prevented the CD8C T cells
impairment. Similarly, impairment of CD8C T cells was
prevented on hMPV-infected PD-1¡/¡mice.152
In other studies, an impairment of lung hMPV-spe-
cific memory CD8C T cells was observed in mMT mice,
which lack B-cells and are used as a model for hMPV
reinfection, which suggest the importance of memory
CD8C T cells in viral clearance during a second infec-
tion.153 Specifically, during reinfection, CD8C T cells had
upregulated several inhibitory receptors, including PD-
1.153 Similarly to it is observed in B7tg mice, blockade of
PD-1 in mMT mice restored lung CD8C T cell effector
functions (i.e., degranulation and cytokine production)
and enhanced viral clearance.153 In other studies, immu-
nization of mMT mice with virus-like particles encoding
the hMPV F and M proteins, generates hMPV F-specific
and M-specific CD8C T cells in lungs, but their function
is impaired, as inhibitory receptors are upregulated on
these cells, similar to what is seen in WT C57BL/6 mice
under a second hMPV infection.149
On the other hand, the depletion of CD8C T cells in
hMPV-infected BALB/c mice resulted in a lower lung
pathological score, although to a lesser degree than
depletion of only CD4C T cells.140 By other part, mice
that was depleted of neutrophils showed a significant
reduction of TNF-a and IL-13 secreted by CD8C T cells
suggesting that neutrophils modulate the production of
these cytokines by CD8C T cells, 141In this manner,
CD8C T cells that infiltrate in the airways and secrete
TNF-a and IL13 contribute to the lung pathology trig-
gered by hMPV infection in mice.140,141
Taken together, CD8C T cells confer protection
against hMPV infection through cytotoxic activities, but
these cells may also contribute to lung pathology.140 Fur-
thermore, the function of these cells can be hampered by
evasion mechanisms of the virus. However, further stud-
ies in humans are still required.
HMPV molecular characteristics and the role of its
viral proteins in immunomodulation
The hMPV genome is comprised of a negative, 13 kb sin-
gle-stranded RNA with the following eight genes: N-P-
M-F-M2-SH-G-L (30 to 50).18 Furthermore, the hMPV
mRNA transcribed by the M2 gene contains two overlap-
ping open reading frames that give rise to the M2–1 and
M2–2 proteins, in similar manner than RSV (Fig. 1).18 In
contrast to RSV, hMPV lacks the NS1 and NS2 genes,
thus the inhibition of the type I IFN pathway is less
robust than the one is observed in RSV.154 The G pro-
tein, a glycoprotein involved in the attachment of the
viral particle,155 inhibits the type I IFN pathway by
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targeting the retinoic-inducible gene 1 (RIG-I), thus it
contributes in inhibiting the antiviral innate response of
the host.156 Likewise, the SH protein, a type 2 transmem-
brane protein with properties as a viroporin, has been
shown to inhibit the NFkb pathway, as infection with a
recombinant virus lacking the SH gene increased the
NFkb-dependent transcription pathway in BALB/c
mice.157 The M protein, which participates in virus
assembly and packaging,158 stimulates the inflammatory
response in vitro by inducing the maturation of mono-
cyte-derived DCs and the secretion of inflammatory
cytokines by these cells, including IL-8, IL-6, IL-1b and
TNF-a (Table 2).159
In addition, the M2–1 protein is critical for hMPV
replication and pathogenesis through its Zinc binding
activity, since a recombinant hMPV carrying mutations
in the zinc binging motif was highly attenuated in cotton
rats.160 This is consistent with studies that demonstrate
that hMPV lacking the M2–1 gene could not replicate in
hamsters.161 However, is not essential for hMPV infec-
tivity and growth in vitro as deletion of the ORF of the
M2–1 protein is dispensable for viral replication in
VERO cells.161 In contrast, the hMPV M2–2 protein,
defined as a terminator factor, since it inhibits viral repli-
cation and transcription,162 interact with MAVS,163 a
protein that links the cytoplasmic viral sensors RIG-I
and the melanoma differentiation associated protein 5
(MDA5) to the downstream TNF receptor-associated
factors (TRAFs) and IkB kinases (IKKs), which are
known to induce the type I IFN-pathway through the
activation of IRF-3 and NFkB.163 Thus, hMPV M2–2
protein contributes in decreasing efficiently the anti-viral
response.
Concluding remarks
Adequate T cell priming is critical for establishing effec-
tive anti-viral immune responses.164,165 Due to the
importance of this process several respiratory viruses,
including hRSV27 and hMPV26 have evolved different
mechanisms to impair T cell activation. Indeed, both of
these viruses impair the T cell response, causing, at least
in part, an aberrant adaptive immune response and poor
immunological memory against hRSV71,166 and
hMPV.136 However, in both cases, memory T cells are
produced after infection but the role of these cells are still
controversial because reinfection episodes are recurrent
in both viruses. By the other hand, the viral mechanism
underlying the inhibition of T cell functions for both
viruses is different.26,131 hRSV impairs T cell activation
by preventing a mature immune synapse assembly, pos-
sibly through the hRSV N protein at the DC plasma
membrane.131 Conversely, hMPV prevents T cell
activation,26 likely though a soluble factor(s) without
interfering with the formation of a mature immune syn-
apse and Golgi polarization in the T cell, as the inhibition
of the TCR signaling is induced with the supernatants of
hMPV-infected DCs.26
Interference at the immune synapse level by hRSV
and T cell activation by hMPV prevents the TH1 polari-
zation required to induce an efficient antiviral
response.26,27 Additionally, hRSV infection triggers detri-
mental inflammation in the airways that is characterized
by an exacerbated TH2 response, thus preventing ade-
quate viral clearance.167 This exacerbated TH2-type
immune response to hRSV could be mediated by TSLP
through activation of the OX40/OX40L interaction,
which consequently stimulates an inappropriate subset
of T cells.80 In addition, IL-25, detected in lungs of
infected hRSV mice, can also contribute to the hRSV-
mediated lung pathology.91
Similarly to hRSV, hMPV activates the TSLP pathway
to induce a mixture of TH2- and TH1-type responses,
most likely through OX40/OX40L interactions.141 This
mixed induction causes pathology and promotes viral
replication in mice lungs.141
Similarly, to T cells response, antibody response is not
effective to reduce reinfection and probably this is medi-
ated by the interaction between B and T cells during
infection. Where T cells that present a polarization to
Th2 in case of hRSV or Th1/Th2 in case of hMPV, mod-
ulate B cell response generating non-protective antibod-
ies. Contrary, has been showed that neutralizing
antibodies are produced after infection with these viruses
but the proportion between neutralizing and non-neu-
tralizing could be mediate a better outcome.
The respective evasion mechanisms induced by each
virus could synergistically act to prevent the activation of
an effective anti-viral T and B cell response during infec-
tion periods. In this sense, is important to advance in
human studies with these two viruses and the mecha-
nism behind its immune modulation.
Abbreviations
AEC Airway epithelial cell
BEC bronchial epithelial cell
BCG Bacillus Calmette-Guerin
CTL cytotoxic T lymphocyte
DC Dendritic cell
hMPV Human metapneumovirus
IFN interferon
M matrix
mDC myeloid dendritic cell
N nucleoprotein
NS non-structural
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pMHC peptide major histocompatibility complex
hRSV human Respiratory Syncytial Virus
SH small hydrophobic
SV Sendai virus
TCR T cell receptor
TSLP Thymic stromal lymphopoietin
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